HCPCS Code Applications and Approvals: April 2023
Quarterly archive · CMS Level II HCPCS24 coding decisions took effect April 1, 2023
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Fourth Quarter 2022 coding cycle, which took effect April 1, 2023.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
April 2023
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| J0208 | PEDMARK Injection, sodium thiosulfate, 100 mg | Fennec Pharmaceuticals, Inc. (Fennec) Intravenous | — | Establish | |
| J0218 | XENPOZYME Injection, olipudase alfa-rpcp, 1 mg | Sanofi Intravenous | — | Establish | |
| J0610 | Calcium Gluconate (Fresenius Kabi) Injection, calcium gluconate (fresenius kabi), per 10 ml | — | Replaced byJ0612 | Discontinue | |
| J0611 | Calcium Gluconate (Wg Critical Care) Injection, calcium gluconate (wg critical care), per 10 ml | — | Replaced byJ0613 | Discontinue | |
| J0612 | Calcium Gluconate (Fresenius Kabi) Injection, calcium gluconate (fresenius kabi), per 10 mg | — | ReplacesJ0610 | Establish | |
| J0613 | Calcium Gluconate (Wg Critical Care) Injection, calcium gluconate (wg critical care), per 10 mg | — | ReplacesJ0611 | Establish | |
| J1449 | Rolvedon Injection, eflapegrastim-xnst, 0.1 mg | Spectrum Pharmaceuticals Subcutaneous | — | Establish | |
| J1747 | Spevigo Injection, spesolimab-sbzo, 1 mg | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Establish | |
| J2403 | IHEEZO 505(b)(2) Chloroprocaine hcl ophthalmic, 3% gel, 1 mg | Harrow Eye, LLC. | — | Establish | |
| J9196 | Gemcitabine Hydrochloride (Accord) Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to J9201, 200 mg | — | — | Establish | |
| J9294 | Pemetrexed (Hospira) 505(b)(2) Injection, pemetrexed (hospira) not therapeutically equivalent to j9305, 10 mg | — | — | Establish | |
| J9296 | Pemetrexed (Accord) 505(b)(2) Injection, pemetrexed (accord) not therapeutically equivalent to j9305, 10 mg | — | — | Establish | |
| J9297 | Pemetrexed (Sandoz) 505(b)(2) Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg | — | — | Establish | |
| Q4265 | NeoStim TL Membrane Neostim tl, per square centimeter | NeoStim, LLC | — | Establish | |
| Q4266 | NeoStim Membrane Neostim membrane, per square centimeter | NeoStim, LLC | — | Establish | |
| Q4267 | NeoStim DL Neostim dl, per square centimeter | NeoStim, LLC | — | Establish | |
| Q4268 | SurGraft FT Surgraft ft, per square centimeter | Surgenex, LLC | — | Establish | |
| Q4269 | SurGraft XT Surgraft xt, per square centimeter | Surgenex, LLC | — | Establish | |
| Q4270 | Complete SL Complete sl, per square centimeter | Samaritan Biologics, LLC | — | Establish | |
| Q4271 | Complete FT Complete ft, per square centimeter | Samaritan Biologics LLC | — | Establish | |
| Q5127 | Stimufend Biosimilar Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg | Fresenius Kabi Subcutaneous | — | Establish | |
| Q5128 | Cimerli Biosimilar Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Coherus BioSciences Intravitreal | — | Establish | |
| Q5129 | Vegzelma Biosimilar Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Celltrion USA, Inc. Intravenous | — | Establish | |
| Q5130 | Fylnetra Biosimilar Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg | Amneal Pharmaceuticals Subcutaneous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Fourth Quarter 2022 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
